LB54640
Sources
registry, as of 2023-11-02Stale
https://clinicaltrials.gov/study/NCT06046443
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 28. Conditions Hypothalamic Obesity. The goal of this study was to determine how well LB54640 (also known as bivamelagon) worked and how safe it was in participants with Hypothalamic Obesity (HO). The study evaluated the effect of bivamelagon on safety, weight reduction, hunger, and quality of life in participants 1
ClinicalTrials.gov NCT06046443 protocol and results modules
registry, as of 2023-09-15Stale
https://clinicaltrials.gov/study/NCT06040372
A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor LG Chem. Enrollment 112. Conditions Obese; Overweight; Healthy. The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects
ClinicalTrials.gov NCT06040372 protocol and results modules
registry, as of 2023-11-02Stale
https://clinicaltrials.gov/study/NCT06041841
A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity. Overall status UNKNOWN. Phases PHASE2. Lead sponsor LG Chem. Enrollment 4. Conditions POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity. The purpose of the study was to assess the efficacy of LB54640 in participants with rare genetic disorders of obesity
ClinicalTrials.gov NCT06041841 protocol and results modules